Kristen Oelschlager Sells 8,586 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) COO Kristen Oelschlager sold 8,586 shares of the company’s stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total transaction of $209,670.12. Following the completion of the transaction, the chief operating officer directly owned 21,874 shares of the company’s stock, valued at $534,163.08. This represents a 28.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Price Performance

CSTL traded up $0.10 on Monday, hitting $24.21. 187,688 shares of the company’s stock traded hands, compared to its average volume of 397,864. The company’s 50 day simple moving average is $21.54 and its 200-day simple moving average is $28.56. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The firm has a market cap of $734.29 million, a price-to-earnings ratio of -55.02 and a beta of 1.00.

Castle Biosciences (NASDAQ:CSTL) last released its earnings results on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, hitting the consensus estimate of ($0.49). The firm had revenue of $84.23 million for the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. As a group, research analysts anticipate that Castle Biosciences, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Robert W. Baird decreased their target price on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. Canaccord Genuity Group reduced their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, April 20th. Weiss Ratings downgraded shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. BTIG Research cut their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a research note on Wednesday, May 13th. Finally, KeyCorp set a $35.00 price objective on Castle Biosciences in a research report on Friday, May 29th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $42.43.

Hedge Funds Weigh In On Castle Biosciences

A number of large investors have recently added to or reduced their stakes in CSTL. RTW Investments LP purchased a new position in shares of Castle Biosciences in the 4th quarter worth approximately $82,283,000. Summit Partners Public Asset Management LLC grew its position in Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock worth $41,184,000 after purchasing an additional 658,725 shares during the last quarter. Eventide Asset Management LLC purchased a new position in shares of Castle Biosciences in the fourth quarter worth $11,864,000. SG Americas Securities LLC grew its holdings in shares of Castle Biosciences by 1,051.8% during the first quarter. SG Americas Securities LLC now owns 244,886 shares of the company’s stock valued at $6,012,000 after buying an additional 223,624 shares during the last quarter. Finally, Wellington Management Group LLP purchased a new position in Castle Biosciences in the 4th quarter worth $8,502,000. 92.60% of the stock is currently owned by institutional investors.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.